Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cancer Germany Clinical Trials

Genentech/Roche's GA101 poised to usurp Rituxan in CLL

This article was originally published in Scrip

Executive Summary

Genentech/Roche's novel product GA101 (obinutuzumab) is continuing its triumph over all challengers in its Phase III CLL11 study, producing significantly improved progression-free survival data over its predecessor MabThera/Rituxan (rituximab) in chronic lymphocytic leukaemia (CLL). However, the extent of its victory is still unclear – news on this will await presentation of the full results, probably at the American Society of Hematology meeting in December.

Table

View full table

Topics

Related Companies

Tags:
Cancer Germany Clinical Trials
Latest Headlines

The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?

NASDAQ Is Nice But Home Provides Comfort For Europe’s Biotechs

Amgen Planning Pivotal Obesity Program For MariTide

Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout

See All
UsernamePublicRestriction

Register

SC022189

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By